The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature

JAK inhibitors are emerging as a promising option for the treatment of immune checkpoint inhibitor-related toxicities. The currently published evidence, primarily from case reports and case series, suggests they have efficacy, particularly in patients who have failed to respond to other cytokine inhibition strategies.